Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Mirto Christofidou"'
Autor:
Stelios F, Assimakopoulos, Vassilis, Karamouzos, Aikaterini, Lefkaditi, Christina, Sklavou, Fevronia, Kolonitsiou, Mirto, Christofidou, Fotini, Fligou, Charalambos, Gogos, Markos, Marangos
Publikováno v:
Le infezioni in medicina. 27(1)
Acinetobacter baumannii has evolved in recent decades as a major problem in carbapenem-resistant gram-negative nosocomial infections, associated with high mortality rates especially in intensive care units (ICUs). Recent reports highlight the increas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b3494fa8b32b5afbca9c4d52b7af7aad
https://pubmed.ncbi.nlm.nih.gov/30882373
https://pubmed.ncbi.nlm.nih.gov/30882373
Autor:
Kalliopi Zachou, Vasiliki Nikolopoulou, Mirto Christofidou, George N. Dalekos, Chrissoula Lambropoulou-Karatza, Athanasios Tsamandas, Christos Triantos, Alexandra Kourakli, Maria Kalafateli, Konstantinos Thomopoulos, Argiris Symeonidis, Eleni Jelastopoulou, Polixeni Lambropoulou, Nikolaos K. Gatselis
Publikováno v:
Journal of Gastrointestinal and Liver Diseases. 24:189-196
Background & Aims: Monotherapy with standard or pegylated interferon (PegIFN) remains the first-line treatment for HCV infection in patients with thalassemia major (ßTM), although its long-term impact is still unknown. We aimed to assess the efficac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbd8d1fa1a1008ad6b37bced1f2153bb
https://doi.org/10.15403/jgld.2014.1121.242.a2b
https://doi.org/10.15403/jgld.2014.1121.242.a2b
Autor:
Chryssoula Labropoulou-Karatza, Polixeni Lampropoulou, Alexandra Kourakli, Vasiliki Nikolopoulou, Konstantinos Thomopoulos, Athanasios Tsamandas, Nikolaos Koukias, Helen Fragopanagou, Dimitra Giannakopoulou, Christos Triantos, Christina Bartzavali, Marina Karakantza, Maria Kalafateli, Mirto Christofidou, George C. Kagadis
Publikováno v:
Annals of Hematology. 92:739-746
Chronic hepatitis C (CHC) and iron overload are the main causes of liver disease in β-thalassemia major (βTM). There is limited data regarding the course of CHC in this population. All patients (n=144) from the thalassemia centre of the University
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33415b2d4f929e05c944fb6ce11e6e1e
https://doi.org/10.1007/s00277-013-1692-6
https://doi.org/10.1007/s00277-013-1692-6